JPMorgan raised the firm’s price target on Travere Therapeutics to $20 from $19 and keeps an Overweight rating on the shares. The analyst updated models in the Smid-cap biotechnology space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics price target raised to $20 from $19 at H.C. Wainwright
- Travere Therapeutics price target raised to $14 from $12 at Barclays
- Travere Therapeutics files automatic mixed securities shelf
- Travere Therapeutics reports Q2 EPS (91c), consensus (86c)